Harrow’s latest price target update leaves its fair value estimate essentially unchanged at about $70.63 per share, even as the underlying narrative around the stock grows more dynamic. With analysts refining their models in response to new data points, these subtle adjustments reflect a deeper reassessment of Harrow’s revenue potential and risk profile. Read on to see how you can track these evolving targets and stay prepared for the next developments in Harrow’s story.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Harrow.

???? Bullish Takeaways

Cantor Fitzgerald has taken one of the most aggressive stances, lifting its target to $94 from $76 while reiterating an Overweight rating. This reflects confidence that Harrow can sustain strong growth even as Vevye revenues modestly trail FY25 guidance.

B. Riley and Lake Street have both raised targets, to $74 from $70 and to $70 from $42 respectively. They point to an expanding pipeline, a clear commercial roadmap, and the potential to scale to $250M plus in quarterly revenue by Q4 2027 as supports for a bullish long term margin and revenue expansion story.

Craig Hallum, now at $64 from $54, highlights underappreciated upside from ophthalmic biosimilars Byooviz and Opuviz. The firm sees meaningful revenue contributions beginning in 2026, reinforcing a thesis of continued top line growth momentum.

Ladenburg has nudged its target to $66 from $64 after Q3. Alongside multiple Buy and Overweight ratings, this suggests analysts broadly reward the company for execution against its roadmap and for building credible long term growth drivers, even as some flag increasing pressure on 2026 delivery.

???? Bearish Takeaways

Even within generally positive research, Cantor Fitzgerald notes that modeled Vevye revenues now fall about $8M short of Harrow's FY25 target. This gap raises the bar for 2026 performance, where new insurance coverage and market share gains must translate into proportional revenue growth.

Across recent target hikes from Craig Hallum, Lake Street, B. Riley, Ladenburg, and Cantor Fitzgerald, the clustering of higher price objectives into the mid to high $60s and above implicitly tightens the margin for error. Execution slippage or slower biosimilar uptake could pose valuation and near term downside risks.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Updated 2025 revenue guidance to a slightly more conservative range of $270M to $280M, while management emphasized that the original goal of exceeding $280M remains attainable with strong execution.

Introduced the Harrow Access for All program, which will cap eligible patients' out of pocket costs at $59 and gradually extend affordable access across branded, generic, and compounded ophthalmic medicines through 2027.

Announced the upcoming launch of BYQLOVI, a clobetasol propionate ophthalmic suspension 0.05%, positioned as an early beneficiary of the Harrow Access for All rollout to support physician adoption of new specialty therapies.

Appointed Deloitte and Touche LLP as the new independent registered public accounting firm for the 2025 fiscal year audit, replacing Crowe LLP following a review and decision by the Audit Committee.

Fair Value: Unchanged at approximately $70.63 per share, indicating a stable long term intrinsic value assessment.

Discount Rate: Edged down slightly from about 6.96% to 6.96%, reflecting a marginally lower implied risk profile.

Revenue Growth: Essentially flat, holding near 39.51%, suggesting no material change in long term top line growth expectations.

Net Profit Margin: Stable at roughly 26.50%, indicating consistent assumptions around long term profitability.

Future P/E: Remains effectively unchanged at about 19.69x, signaling a steady view on Harrow’s forward valuation multiple.

Narratives are investor-created stories that sit behind the numbers, connecting a company’s strategy and risks to explicit forecasts for revenue, earnings, margins, and ultimately fair value. On Simply Wall St’s Community page, millions of investors use Narratives as an easy, accessible way to link Harrow’s evolving story to a live valuation and to compare Fair Value with the current share price, dynamically updated as fresh news and earnings arrive.

Head over to the Simply Wall St Community and follow the Narrative on Harrow to stay on top of:

How accelerating demand for VEVYE, IHEEZO, TRIESENCE, and biosimilars could be linked to long-term revenue and margin expansion.

Whether execution risks, pricing pressure, and product concentration might affect projected EPS growth to $209m by 2028.

How changes in analyst forecasts and discount rates may shift Harrow’s Fair Value relative to today’s share price over time.

Curious how numbers become stories that shape markets? Explore Community Narratives

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include HROW.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com